SEC filings and other documents

Q2 revenue up 8% to $24.3M, with strong AI-driven growth and robust cash position.

Integrated AI ecosystem and cross-selling drive future growth, with major upside in FY 2027.

All proposals passed with strong support; no shareholder questions were raised.

Integrated AI and cloud platform aims to accelerate drug development and drive sustainable growth.

Services growth and margin gains offset software softness; FY26 guidance reaffirmed.

FY25 delivered 13% revenue growth; FY26 guidance flat to 4% with AI-driven pricing upside.

Biosimulation and AI drive drug development efficiency, with regulatory trends fueling future growth.

Biosimulation growth, AI integration, and regulatory support drive expansion despite industry headwinds.

Revenue up 10% with strong software, but services and market headwinds cut guidance.

Q2 revenue up 23% YoY, strong software growth, and $5M MC contract to drive H2 gains.

Monolix and Pro-ficiency lead growth as integration and industry adoption drive margin gains.

Pro-ficiency acquisition boosts growth, with software focus driving stable, recurring revenue.

Strong software growth and robust backlog support reaffirmed 2025 guidance.